Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BIOC Stock Summary
In the News
BIOC Financial details
Company Rating
Buy
Market Cap
1.14M
Income
-34.9M
Revenue
-3.44M
Book val./share
0.28
Cash/share
6.4
Dividend
-
Dividend %
-
Employees
50
Optionable
No
Shortable
Yes
Earnings
20 Nov 2023
P/E
-0.01
Forward P/E
-
PEG
-0
P/S
-0.33
P/B
1.55
P/C
0.07
P/FCF
-0.06
Quick Ratio
1.52
Current Ratio
1.81
Debt / Equity
39.97
LT Debt / Equity
33.4
-
-
EPS (TTM)
-58.12
EPS next Y
-
EPS next Q
-
EPS this Y
890.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-53.58%
Revenue last 5Y
51.4%
Revenue Q/Q
-12.48%
EPS Q/Q
-71.59%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
107.76%
Inst Trans
2.78%
ROA
-158%
ROE
-357%
ROC
-2.17%
Gross Margin
556%
Oper. Margin
1088%
Profit Margin
1016%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.32-27.0
52W High
-
52W Low
-
RSI
27
Rel Volume
0.31
Avg Volume
2.16M
Volume
671.57K
Perf Week
97.68%
Perf Month
-
Perf Quarter
-
Perf Half Y
-20.46%
-
-
-
-
Beta
0.595
-
-
Volatility
0.13%, 0.17%
Prev Close
720.57%
Price
0.4349
Change
624.83%
BIOC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 348.48 | 80.28 | 69.55 | 124.36 | 45.76 | |
Net income per share | -2.63K | -357.41 | -43.16 | -5.73 | -56.78 | |
Operating cash flow per share | -2.4K | -334.68 | -50.11 | 7.49 | -23.52 | |
Free cash flow per share | -2.41K | -345.36 | -52.31 | 4.3 | -24.94 | |
Cash per share | 367.04 | 135.06 | 36.39 | 58.6 | 22.82 | |
Book value per share | 326.21 | 162.64 | 60 | 76.1 | 15.68 | |
Tangible book value per share | 326.21 | 162.64 | 60 | 76.1 | 15.68 | |
Share holders equity per share | 326.21 | 162.64 | 60 | 76.1 | 15.68 | |
Interest debt per share | 207.73 | 67.1 | 36.89 | 26.32 | 21.99 | |
Market cap | 2.41M | 5.99M | 52.59M | 53.49M | 8.99M | |
Enterprise value | 609.54K | -769.83K | 50.45M | 37.3M | 8.2M | |
P/E ratio | -0.1 | -0.24 | -3.09 | -18.94 | -0.28 | |
Price to sales ratio | 0.74 | 1.08 | 1.92 | 0.87 | 0.35 | |
POCF ratio | -0.11 | -0.26 | -2.66 | 14.5 | -0.68 | |
PFCF ratio | -0.11 | -0.25 | -2.55 | 25.25 | -0.64 | |
P/B Ratio | 0.79 | 0.53 | 2.22 | 1.43 | 1.01 | |
PTB ratio | 0.79 | 0.53 | 2.22 | 1.43 | 1.01 | |
EV to sales | 0.19 | -0.14 | 1.84 | 0.61 | 0.32 | |
Enterprise value over EBITDA | -0.03 | 0.03 | -3.26 | -15.48 | -0.26 | |
EV to operating cash flow | -0.03 | 0.03 | -2.55 | 10.11 | -0.62 | |
EV to free cash flow | -0.03 | 0.03 | -2.44 | 17.61 | -0.58 | |
Earnings yield | -10.21 | -4.11 | -0.32 | -0.05 | -3.57 | |
Free cash flow yield | -9.35 | -3.97 | -0.39 | 0.04 | -1.57 | |
Debt to equity | 0.53 | 0.23 | 0.52 | 0.34 | 1.37 | |
Debt to assets | 0.19 | 0.14 | 0.26 | 0.21 | 0.39 | |
Net debt to EBITDA | 0.07 | 0.29 | 0.14 | 6.72 | 0.02 | |
Current ratio | 1.3 | 2.5 | 2.61 | 3.88 | 2.97 | |
Interest coverage | -78.01 | -11.08 | -6.61 | -8.31 | -101.21 | |
Income quality | 0.91 | 0.92 | 1.11 | -1.31 | 0.41 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.18 | 1.26 | 0.36 | 0.21 | 0.62 | |
Research and developement to revenue | 1.37 | 0.85 | 0.19 | 0.08 | 0.24 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.03 | 0.04 | -0.43 | 0.06 | |
Capex to revenue | -0.04 | -0.13 | -0.03 | -0.03 | -0.03 | |
Capex to depreciation | -0.18 | -0.95 | -0.87 | -0.6 | -0.49 | |
Stock based compensation to revenue | 0.19 | 0.16 | 0.03 | 0.04 | 0.12 | |
Graham number | 4.4K | 1.14K | 241.4 | 99.08 | 141.52 | |
ROIC | -3.85 | -1.39 | -0.31 | -0.04 | -0.97 | |
Return on tangible assets | -2.81 | -1.39 | -0.36 | -0.05 | -1.04 | |
Graham Net | -86.85 | 84.2 | 5.53 | 35.72 | -12.61 | |
Working capital | 1.4M | 8.33M | 20.1M | 33.92M | 10.84M | |
Tangible asset value | 3.04M | 11.2M | 23.69M | 37.48M | 8.86M | |
Net current asset value | 303.1K | 7.36M | 8.83M | 22.76M | -5.67M | |
Invested capital | 0.53 | 0.23 | 0.52 | 0.34 | 1.37 | |
Average receivables | 1.38M | 2.55M | 8.84M | 13.97M | 7.97M | |
Average payables | 1.65M | 2.03M | 5.19M | 7.81M | 4.38M | |
Average inventory | 542.96K | 677.6K | 1.35M | 2.29M | 1.7M | |
Days sales outstanding | 176.79 | 232.86 | 188.01 | 82.15 | 30.36 | |
Days payables outstanding | 74.07 | 66.89 | 143.09 | 70.03 | 19.55 | |
Days of inventory on hand | 21.32 | 25.54 | 33.01 | 25.62 | 9.72 | |
Receivables turnover | 2.06 | 1.57 | 1.94 | 4.44 | 12.02 | |
Payables turnover | 4.93 | 5.46 | 2.55 | 5.21 | 18.67 | |
Inventory turnover | 17.12 | 14.29 | 11.06 | 14.25 | 37.57 | |
ROE | -8.08 | -2.2 | -0.72 | -0.08 | -3.62 | |
Capex per share | -15.57 | -10.68 | -2.2 | -3.19 | -1.43 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 18.83 | 9.86 | -18.08 | 1.15 | 0.57 | |
Net income per share | -9.59 | -9.73 | -32.57 | -12.32 | -3.5 | |
Operating cash flow per share | -7.17 | -7.19 | -7.46 | -10.55 | -2.98 | |
Free cash flow per share | -7.55 | -7.82 | -7.7 | -10.7 | -3.07 | |
Cash per share | 40.69 | 31.81 | 22.68 | 11.53 | 6.4 | |
Book value per share | 57.59 | 48.57 | 15.58 | 4.13 | 0.28 | |
Tangible book value per share | 57.59 | 48.57 | 15.58 | 4.13 | 0.28 | |
Share holders equity per share | 57.59 | 48.57 | 15.58 | 4.13 | 0.28 | |
Interest debt per share | 22.39 | 21.73 | 21.37 | 19.8 | 11.23 | |
Market cap | 15.89M | 15.64M | 9.04M | 5.99M | 1.25M | |
Enterprise value | 5.43M | 9.88M | 8.26M | 10.8M | 6.21M | |
P/E ratio | -0.73 | -0.71 | -0.12 | -0.21 | -0.09 | |
Price to sales ratio | 1.5 | 2.8 | -0.88 | 8.9 | 2.13 | |
POCF ratio | -3.93 | -3.84 | -2.13 | -0.97 | -0.41 | |
PFCF ratio | -3.73 | -3.53 | -2.07 | -0.95 | -0.39 | |
P/B Ratio | 0.49 | 0.57 | 1.02 | 2.47 | 4.32 | |
PTB ratio | 0.49 | 0.57 | 1.02 | 2.47 | 4.32 | |
EV to sales | 0.51 | 1.77 | -0.8 | 16.05 | 10.55 | |
Enterprise value over EBITDA | -1.07 | -1.94 | -0.45 | -1.67 | -1.1 | |
EV to operating cash flow | -1.34 | -2.42 | -1.95 | -1.74 | -2.01 | |
EV to free cash flow | -1.28 | -2.23 | -1.89 | -1.72 | -1.95 | |
Earnings yield | -0.34 | -0.35 | -2.05 | -1.21 | -2.9 | |
Free cash flow yield | -0.27 | -0.28 | -0.48 | -1.05 | -2.54 | |
Debt to equity | 0.38 | 0.45 | 1.37 | 4.77 | 39.97 | |
Debt to assets | 0.21 | 0.24 | 0.39 | 0.5 | 0.52 | |
Net debt to EBITDA | 2.05 | 1.13 | 0.04 | -0.74 | -0.88 | |
Current ratio | 4.55 | 5.13 | 2.97 | 2.07 | 1.81 | |
Interest coverage | -32.88 | -107.25 | -395.81 | -154.3 | -122.28 | |
Income quality | 0.77 | 0.74 | 0.23 | 0.87 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.41 | 0.55 | -0.19 | 4.44 | 5.93 | |
Research and developement to revenue | 0.16 | 0.24 | -0.12 | 1.55 | 0.69 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.09 | 0.03 | 0.01 | 0.03 | |
Capex to revenue | -0.02 | -0.06 | 0.01 | -0.14 | -0.16 | |
Capex to depreciation | 24.11 | -0.87 | -0.31 | -0.15 | -0.26 | |
Stock based compensation to revenue | 0.06 | 0.08 | 0.01 | 0.47 | 0.35 | |
Graham number | 111.51 | 103.11 | 106.84 | 33.85 | 4.7 | |
ROIC | -0.09 | -0.11 | -0.56 | -0.28 | -0.28 | |
Return on tangible assets | -0.09 | -0.11 | -0.6 | -0.31 | -0.16 | |
Graham Net | 20.23 | 12.73 | -12.53 | -21.46 | -13.8 | |
Working capital | 34.17M | 29.49M | 10.84M | 4.7M | 3.96M | |
Tangible asset value | 32.46M | 27.52M | 8.86M | 2.43M | 290K | |
Net current asset value | 18.09M | 13.05M | -5.67M | -11.48M | -12.95M | |
Invested capital | 0.38 | 0.45 | 1.37 | 4.77 | 39.97 | |
Average receivables | 16.86M | 16.57M | 8.96M | 1.63M | 956K | |
Average payables | 6.45M | 3.94M | 2.28M | 1.53M | 1.5M | |
Average inventory | 2.74M | 2.07M | 1.33M | 730.5K | 627.5K | |
Days sales outstanding | 147.38 | 254 | -18.82 | 148.71 | 122.24 | |
Days payables outstanding | 54.18 | 47.37 | 31.82 | 45.56 | 51.78 | |
Days of inventory on hand | 25.23 | 29.56 | 15.82 | 20.92 | 19.45 | |
Receivables turnover | 0.61 | 0.35 | -4.78 | 0.61 | 0.74 | |
Payables turnover | 1.66 | 1.9 | 2.83 | 1.98 | 1.74 | |
Inventory turnover | 3.57 | 3.04 | 5.69 | 4.3 | 4.63 | |
ROE | -0.17 | -0.2 | -2.09 | -2.98 | -12.52 | |
Capex per share | -0.39 | -0.63 | -0.24 | -0.15 | -0.09 |
BIOC Frequently Asked Questions
What is Biocept, Inc. stock symbol ?
Biocept, Inc. is a US stock , located in San diego of Ca and trading under the symbol BIOC
What is Biocept, Inc. stock quote today ?
Biocept, Inc. stock price is $0.4349 today.
Is Biocept, Inc. stock public?
Yes, Biocept, Inc. is a publicly traded company.